{"product_id":"abcam-ab263928","title":"Abcam, ab263928, Human FHL2 knockout U-2 OS cell lysate","description":"\u003cp\u003eSize: 1Kit\u003cbr\u003e\nFHL2 KO cell lysate available now. KO validated by Immunocytochemistry, Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR\/Cas9 X = 1 bp insertion Frameshift = 96.21%.\u003cbr\u003e\nKey facts\u003cbr\u003e\nCell type:U-2 OS,\u003cbr\u003e\nSpecies or organism:Human,\u003cbr\u003e\nTissue:Bone,\u003cbr\u003e\nKnockout validation:Immunocytochemistry,Next Generation Sequencing,Western blot,\u003cbr\u003e\nMutation description:Knockout achieved by CRISPR\/Cas9 X = 1 bp insertion Frameshift = 96.21%,\u003cbr\u003e\nDisease:Osteosarcoma\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nKnockout cell lysate achieved by CRISPR\/Cas9.\u003cbr\u003e\nREACH authorisation\u003cbr\u003e\nAbcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.\u003cbr\u003e\nIt is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.\u003cbr\u003e\nLysate preparation:\u003cbr\u003e\nOur lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).\u003cbr\u003e\nThis means that the protein of interest is denatured.\u003cbr\u003e\nIf you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.\u003cbr\u003e\nUser storage instructions:\u003cbr\u003e\nLyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.\u003cbr\u003e\nThis product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our\u003cbr\u003e\nlimited use license\u003cbr\u003e\npatent pages\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nGene name-FHL2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Immunocytochemistry, Next Generation Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nThe FHL2 protein also known as Four and a Half LIM Domains Protein 2 plays an important role in cellular mechanics. Its molecular mass is approximately 32 kDa. FHL2 is expressed in various tissues with significant presence in cardiac and skeletal muscles as well as the liver. It is involved in the regulation of gene expression by binding to other proteins and DNA through its LIM domains. This ability allows FHL2 to influence cellular structures and functions integrally.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nThe FHL2 protein serves critical functions in muscle development and differentiation. It operates as part of a multiprotein complex that interacts with cytoskeletal components contributing importantly to muscle cell adhesion and communication. Moreover FHL2 engages in transcriptional regulation and acts as a coactivator or corepressor of specific transcription factors influencing gene expression patterns relevant to muscle function and maintenance.\u003cbr\u003e\nPathways\u003cbr\u003e\nThe FHL2 protein plays significant roles in Wnt and MAPK signaling pathways. In the Wnt signaling pathway FHL2 regulates the transcriptional activity of beta-catenin an essential component of the pathway involved in cell growth and differentiation. Additionally FHL2 contributes to the MAPK signaling pathway by influencing interactions between upstream regulators and downstream targets modulating cellular responses to external stimuli. Through these pathways FHL2 interacts with various proteins including GATA4 and TEF-1 which are vital for its regulatory functions.\u003cbr\u003e\nFHL2 has associations with certain cancers like prostate cancer and cardiomyopathy. In prostate cancer FHL2 overexpression leads to increased tumor progression and is often linked to androgen receptors promoting malignant transformation. In cardiomyopathy alterations in FHL2 expression affect heart muscle integrity and function sometimes in conjunction with interactions involving desmin an important structural protein. Understanding FHL2's connections to these diseases offers insights into potential therapeutic targets.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46845074505897,"sku":"ab263928","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/abcam-ab263928","provider":"Iright","version":"1.0","type":"link"}